Introduction
With improved living standards and advances in medical treatment, the respective life expectancies of males and females in Hong Kong have increased from 72.3 years and 78.5 years in 1981, to 81.2 years and 86.7 years in 2014. 1 Aortic stenosis is one of the most common valvular heart diseases in the ageing population. 2 The prevalence of aortic stenosis is up to 4.6% in people older than 75 years. 2 After onset of symptoms, including the classic triad of chest pain, heart failure or syncope, patients with severe aortic New knowledge added by this study • Transcatheter aortic valve implantation (TAVI) is safe and feasible in patients with symptomatic severe aortic valve stenosis and high surgical risk.
• Clinical outcome was very promising for up to 1 year in patients who underwent TAVI.
Implications for clinical practice or policy
• TAVI should be offered to patients with symptomatic severe aortic stenosis who are deemed inoperable or at high risk for open heart surgery.
Surgical aortic-valve replacement (SAVR) is the gold standard of treatment for patients with symptomatic severe aortic stenosis. 3, 4, 6, 7 Many do not receive surgical treatment, however, because of advanced age or multiple co-morbidities. 8 Transcatheter aortic valve implantation (TAVI) has recently been developed as an option for these patients who are inoperable or at high risk of SAVR. 9, 10 Queen Elizabeth Hospital is the first hospital ORIGINAL ARTICLE patients, respectively. A permanent pacemaker was implanted in seven (12.5%) patients. Both hospital and 30-day mortalities were 1.8%. The 1-year allcause and cardiovascular mortality rates were 12.5% and 7.1%, respectively.
Conclusions:
Transcatheter aortic valve implantation has been developed as an alternative treatment for patients with symptomatic severe aortic stenosis who are deemed inoperable or high risk for surgery. Our results are very promising and comparable with those of major clinical trials. 
Methods
In order to introduce TAVI into Hong Kong, a Structural Heart Team comprising cardiologists, cardiac surgeons, cardiac anaesthesiologists, radiologists and cardiac nurses, was formed in early 2010 in Queen Elizabeth Hospital, which is a regional hospital in Hong Kong. All potential patients were assessed and interviewed independently by cardiologists and cardiac surgeons. Clinical assessment of functional status, transthoracic echocardiogram, transoesophageal echocardiogram (TEE), computed tomographic (CT) scan, and conventional angiogram were performed according to the protocol to assess the risks of SAVR and suitability for TAVI. The Structural Heart Team would undertake these investigations to assess whether the risks of the patients were too high for SAVR and if they were suitable for TAVI.
The correct size of the TAVI device was based on the aortic annular dimensions measured by TEE and CT scan. The preferred route of device introduction was via the femoral artery. Based on findings such as the vessel diameter, degree of calcification and tortuosity found on CT imaging, the subclavian artery or direct aortic approach was also a valid alternative. The device was implanted under fluoroscopic guidance and the correct position monitored by fluoroscopy and TEE. Patients underwent transthoracic echocardiogram prior to discharge to assess device function and exclude pericardial effusion. Post-discharge, regular clinic visits, and serial transthoracic echocardiograms were arranged to assess progress and monitor any adverse events. All complications were reported to an independent Safety Monitoring Committee of the hospital.
The first TAVI device was used in December 2010 and was a self-expanding Medtronic CoreValve device (Medtronic, Minneapolis [MN], US) [ Fig  1a] . Subsequent to the introduction of its secondgeneration Evolut R (Medtronic, Minneapolis [MN], US) in 2015 (Fig 1b) , it was used in most cases due to its improved design of recapture/repositioning ability and its smaller sheath size (18 
treat a broad spectrum of patients with a wide variety of clinical and anatomical challenges. The choice of valve type was made by the Structural Heart Team, based on the anatomy of the native aortic valve, size, and calcification of iliofemoral vessels and need for alternative access.
All patients who underwent TAVI during the study period were entered into the TAVI registry of our hospital. Their baseline characteristics, procedural details, device used, and clinical outcomes were recorded. They attended for regular follow-up in our structural heart disease clinic as well as regular echocardiographic monitoring. Follow-up data were also added to the registry. Any patient who defaulted follow-up was contacted; if they had died, cause of death was retrieved from their electronic patient record of Hospital Authority of Hong Kong.
We retrieved and analysed the data of the TAVI registry. Descriptive statistics were used to report baseline characteristics, procedural results, and clinical outcomes. Analysis was performed using the Microsoft Office Excel (Mac version 2011; Microsoft, Washington, US). The study was performed in accordance with the principles outlined in the Declaration of Helsinki.
Results

Baseline characteristics
From December 2010 to September 2015, a total of 56 patients with symptomatic severe aortic stenosis underwent TAVI. Their baseline characteristics are outlined in Table 1 . Their mean (± standard deviation) age was 81.9 ± 4.8 years, and the majority (64.3%) were male. The prevalence of severe comorbidities was predicted as high, with a mean logistic EuroSCORE of 22.6% ± 13.4% and a mean Society of Thoracic Surgeons score of 7.0 ± 4.4. Several variables were taken into account when calculating these risk scores, such as age, symptoms at presentation, current haemodynamic status, left ventricular systolic function, baseline renal function, New York Heart Association (NYHA) functional class, and presence of other co-morbidities such as peripheral artery disease, pulmonary disease, and cerebrovascular disease. The mean left ventricular ejection fraction (LVEF) was 54.8% ± 12.9%. Most patients had various degrees of heart failure symptoms with 22 (39.3%), 26 (46.4%), and six (10.7%) patients in NYHA class II, III, and IV, respectively. All patients had severe aortic stenosis on echocardiography, defined by standard criteria with a mean aortic valve area of 0.7 cm 2 ± 0.2 cm 2 and mean aortic transvalvular pressure gradient of 49.0 mm Hg ± 12.9 mm Hg.
Procedural outcomes
The procedural outcomes are summarised in Left ventricular ejection fraction (%) 54.8 ± 12.9
Aortic orifice area (cm 
Adverse events
The safety endpoints and clinical outcomes are outlined in Table 3 . Conversion to open heart surgery after the procedure was necessary in two patients, one of whom had a calcified valvular leaflet that dislodged into the left atrium after device implantation and required open exploration. The other patient had incessant ventricular fibrillation, possibly due to coronary obstruction during the procedure, and required emergent cardiopulmonary bypass and open heart surgery. Pre-procedural CT revealed adequate coronary height (both left coronary and right coronary ostium >16 mm above annular plane) and adequate sinus of Valsalva diameters. The coronary obstruction was thought to be due to dislodged calcified nodules from the aortic valve leaflets. This patient eventually died despite SAVR under extracorporeal membrane oxygenation support, and was the only hospital mortality (1.8%). Stroke occurred in one (1.8%) patient within 30 days. New conduction abnormalities requiring permanent pacing were present in seven (12.5%) patients. There were major access-related vascular complications in five (8.9%) patients and three (5.4%) had acute kidney injury stage 2 although none required long-term dialysis and no patient had acute kidney injury stage 3 (Table 3) .
Follow-up results
Most patients (55/56, 98.2%) either had regular follow-up or died. Only one patient who relocated to Mainland China was lost to follow-up, although his doctor keeps us updated regularly about his condition. The longest follow-up period was 5 years. The 30-day mortality rate was 1.8%. The NYHA functional class of patients at baseline and at 30 days is outlined in Figure 2 ; 92% of patients improved by at least one functional class. The mean LVEF was 57.9% ± 10.9% at 30 days. The mean aortic valve area improved to 1.94 cm 2 ± 0.37 cm 2 and mean aortic transvalvular pressure gradient improved to 8.1 mm Hg ± 3.4 mm Hg (Fig 3) . These improvements persisted at 6-month and 1-year follow-up assessment. The 6-month all-cause and cardiovascular mortalities were 8.9% and 5.4%, respectively. The 1-year all-cause and cardiovascular mortalities were 12.5% and 7.1%, respectively (Table  3) . Causes of 1-year mortality included myocardial infarction, heart failure with cardiogenic shock, liver failure, pneumonia, and sepsis with disseminated intravascular coagulopathy.
Discussion
This is the first report to describe the clinical experience of TAVI in a major tertiary referral hospital, which is also the first hospital in Hong Kong to introduce this technology and having the largest case volume in Hong Kong up until the end of 2015. The clinical outcomes of our cohort show very promising results. Since 2010, there have been several landmark clinical trials describing the initial clinical outcome of TAVI in both high-surgicalrisk and inoperable patients. The PARTNER 1 was a multicentre prospective randomised controlled trial to investigate the balloon-expandable Edwards SAPIEN valve (Edwards Lifesciences). PARTNER 1B arm randomised inoperable patients to TAVI or best medical treatment and showed a 20% absolute reduction in mortality rate at 1 year with TAVI. 9 The PARTNER 1A arm randomised patients with high surgical risk to either TAVI or SAVR and TAVI was shown to be non-inferior to SAVR in terms of mortality rate at 1 year (24% vs 26.8%; P=0.44).
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The US CoreValve pivotal trial randomised patients with high surgical risk to either TAVI using the selfexpanding CoreValve or SAVR and demonstrated a significant reduction in mortality rate at 1 year in the TAVI group compared with the SAVR group (14.2% vs 19.1%; P=0.04). 10 The relatively high 1-year mortality rate in those clinical trials is mainly due to their baseline multiple co-morbidities and the advanced age (mean age, 80 years) of patients. The 1-year mortality rate of 12.5% in our cohort compares well with these landmark trials. The risk profile of our patient group is nonetheless not lower (logistic EuroSCORE of 22% in our group vs 18% in CoreValve pivotal trial). This high baseline risk factor accounts for the high 1-year mortality rate although a significant proportion was related to non-cardiac causes (3 out of 7). The current view is to avoid treating the patients with too high risk and who will not benefit from this high-risk procedure. A reasonable 1-year expected survival is also a prerequisite. 12, 13 Other complication rates of our cohort also compared well with the landmark trials. Significant aortic regurgitation secondary to paravalvular leak (PVL) is a unique problem not uncommonly encountered following TAVI in contrast to patients who undergo SAVR in whom there is usually no residual leakage. 14, 15 One study showed that even mild PVL after TAVI is associated with higher mortality rate at 2 years. 16 Treatment of significant PVL is by post-dilation, putting in another valve (so called 'valve in valve') or using a vascular plug. The rate of moderate or severe PVL in both the PARTNER 1B 9 and US CoreValve pivotal trial 10 was approximately 7%. No moderate or severe PVL was noted in our Aortic valve area study due to the high rate of using two valves ('valve in valve') in 16% of our cohort compared with the reported 4% rate in the US CoreValve pivotal trial. With increasing experience and availability of a repositionable device, however, progressively fewer cases required more than one valve.
Some of the complications after TAVI are more disabling than others, such as stroke. The major stroke rate in both the PARTNER and US CoreValve pivotal trial was approximately 5%. 9, 10 Major stroke rate in one meta-analysis of more than 10 000 patients was 3.3%. 17 Clinical stroke occurred in only one (1.8%) patient in our cohort. This is probably because of our small sample size, as well as the random and unpredictable nature of this complication. More cases of stroke would be expected if more patients were treated. The latest clinical trial using next-generation TAVI devices resulted in a much lower rate of stroke after TAVI (0.9% at 30 days and 2.4% at 1 year for high-risk patients). 18 The aetiology of stroke after TAVI is multifactorial and includes embolism of valvular material during balloon valvuloplasty, device manipulation across an atheromatous aorta, and atrial fibrillation. 19 Multiple strategies to reduce periprocedural stroke have been attempted including direct stenting, avoidance of pre-or post-dilation, use of cerebral protection devices and different antithrombotic regimens. 20, 21 Currently, randomised trials are underway to determine whether cerebral protection devices are useful in reducing periprocedural stroke. 22 Conduction abnormality is another common event following TAVI. The reported rate of permanent pacemaker implantation to treat highgrade heart block varies from 10% to 30% and it depends very much on type and implantation depth of the device. [23] [24] [25] [26] The rate reported in the US CoreValve pivotal trial was 20% at 1 month and 22% at 1 year. 10 The permanent pacemaker implantation rate in our cohort was 12.5% with the majority of our cases having a self-expandable valve. In our cohort, most pacemakers were implanted earlier on in the study period when we were more cautious about treating post-procedural conduction abnormalities.
Major vascular complications occurred in approximately 6% of patients in the US CoreValve pivotal trial and 11% in PARTNER 1 trial.
9,10 Rates of major vascular complications in different observational and randomised trials range from 5% to 17%. 27 The lower rate in the US CoreValve pivotal trial can be explained by the smaller size of the introducer sheath for CoreValve (18 Fr) compared with the much bigger 22-24 Fr sheath for the firstgeneration SAPIEN device in the PARTNER 1 trial. 9 For the same reason and the relative smaller size of peripheral vessels in an Asian population, we would expect a higher rate of vascular complications. Indeed, the major vascular complication rate in our cohort was 8.9%, which is compatible with the worldwide standard. This is the result of our comprehensive use of CT angiogram for all cases from the beginning of the cohort to delineate the size of the peripheral vessels and better plan of procedural strategies.
Overall, the success of the procedure depends not only on the technical requirement in a very highrisk group of patients but also a comprehensive, multidisciplinary team approach. This 'heart team' approach is the cornerstone of the rapidly developing field of structural heart intervention and preferred strategies in dealing with anticipated complications. 27 After the success in treating high-risk patients with aortic stenosis, the recently published PARTNER 2 trial evaluated TAVI and SAVR in patients with intermediate surgical risk. It randomised patients with intermediate surgical risk to either TAVI or SAVR; TAVI was non-inferior to SAVR in terms of all-cause mortality and disabling stroke at 2 years (19.3% in TAVI group vs 21.1% in SAVR group; P=0.25). 28 Another major trial testing TAVI in intermediate-risk patients, the SURTAVI Trial (ClinicalTrials.gov number NCT01586910), has completed patient recruitment and the results will be available very soon.
Limitations
The limitations of the current study include the relatively small sample size and a single-centre early experience. The technology is evolving and loweror intermediate-risk patients are being treated in various clinical trials. With an increasing awareness of the disease and referrals from around the territory, the population being treated is expected to increase in the coming years.
Conclusions
The technique TAVI has been developed as an alternative treatment for patients with symptomatic severe aortic stenosis who are deemed inoperable or high risk for surgery. It has been proven in major randomised controlled trials to have an acceptable complication rate and durability in the medium term. Our results are very promising and comparable with those of major clinical trials. Long-term clinical outcomes should be diligently monitored.
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